Apimeds Pharmaceuticals US, Inc. (APUS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US03771D2018
Price
2.27 USD
Market cap
3.43 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
Apimeds Pharmaceuticals US, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -11.91 m USD |
| EBIT | -5.83 m USD |
| Net income | -6.00 m USD |
| Diluted EPS – continuing operations | -0.55 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
More stocks
- PharmaCyte Biotech, Inc. (PMCB)
- DNA X, Inc. (SONM)
- Abpro Holdings, Inc. (ABPO)
- Alaunos Therapeutics, Inc. (TCRT)
- MAGELLAN COPPER & GOLD Corp (MAGE)
- Global Warming Solutions, Inc. (GWSO)
- GRI Bio, Inc. (GRI)
- Healthcare Triangle, Inc. (HCTI)
- Fathom Holdings Inc. (FTHM)
- PATRIOT GOLD CORP (PGOL)
- Reliance Global Group, Inc. (EZRA)
- Singularity Future Technology Ltd. (SGLY)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.